He Xiao-Yan, Liao Yu-Dong, Guo Xiao-Qing, Wang Robin, Xiao Zhen-Yu, Wang Yan-Gang
Department of Oncology, Ganzhou People's Hospital, Ganzhou, 341000, China.
Ganzhou Medical School, Ganzhou, 341000, China.
Mol Neurobiol. 2016 Apr;53(3):1856-1861. doi: 10.1007/s12035-015-9140-3. Epub 2015 Mar 20.
Many studies have shown that microRNAs have important roles in the development and progression of various cancers. Recent studies also showed that microRNA-21 expression may be associated with the prognosis of patients with several common cancers. However, there was still lack of evidence for the prognostic role of microRNA-21 expression in brain tumors. We performed a systemic review and meta-analysis of published and unpublished studies to assess the prognostic role of microRNA-21 expression in patients with brain tumors. PubMed, Embase, and Google Scholar databases were searched for eligible studies with data assessing the prognostic role of microRNA-21 expression in brain tumors. Pooled hazard ratios (HRs) of microRNA-21 expression for overall survival and 95% confidence intervals (CI) were calculated. Six studies from five publications were finally included into the meta-analysis. Those six studies included a total of 747 patients with brain tumors and 654 patients with gliomas. For overall survival, the pooled HR of higher microRNA-21 expression in patients with brain tumors was 1.82 (95% CI 1.29-2.58, P = 0.001). In patients with gliomas, the HR for overall survival of higher microRNA-21 expression was 1.83 (95% CI 1.09-3.09, P = 0.023). Sensitivity analysis by omitting one study by turns also showed there was no obvious influence of individual study on the pooled HRs. There was no obvious risk of publication bias in the meta-analysis. The present meta-analysis suggests that microRNA-21 is associated with the prognosis of patients with brain tumors, and high expression of microRNA-21 can predict poor prognosis in patients with brain tumors.
许多研究表明，微小RNA在各种癌症的发生和发展中发挥着重要作用。近期研究还显示，微小RNA-21的表达可能与几种常见癌症患者的预后相关。然而，关于微小RNA-21表达在脑肿瘤中的预后作用仍缺乏证据。我们对已发表和未发表的研究进行了系统综述和荟萃分析，以评估微小RNA-21表达在脑肿瘤患者中的预后作用。检索了PubMed、Embase和谷歌学术数据库，以查找评估微小RNA-21表达在脑肿瘤中预后作用的数据的合格研究。计算了微小RNA-21表达对总生存期的合并风险比（HR）和95%置信区间（CI）。最终，五项出版物中的六项研究被纳入荟萃分析。这六项研究共纳入747例脑肿瘤患者和654例神经胶质瘤患者。对于总生存期，脑肿瘤患者中微小RNA-21高表达的合并HR为1.82（95%CI 1.29-2.58，P = 0.001）。在神经胶质瘤患者中，微小RNA-21高表达的总生存期HR为1.83（95%CI 1.09-3.09，P = 0.023）。轮流剔除一项研究进行的敏感性分析也显示，个别研究对合并HR没有明显影响。荟萃分析中没有明显的发表偏倚风险。本荟萃分析表明，微小RNA-21与脑肿瘤患者的预后相关，微小RNA-21的高表达可预测脑肿瘤患者的不良预后。
